PTC Therapeutics, a biopharmaceutical company, has successfully completed patient enrollment in its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy. Accrual
The study is an open-label Phase I clinical trial of the safety and tolerability of a single infusion of autologous CD4+ T cells genetically modified at the CCR5
The supplemental biologics license application (sBLA), submitted to the FDA in December 2008, was based on a re-analysis and resubmission of data from a pivotal Phase III acute
Zealand Pharma, a Denmark-based biopharmaceutical company, has advanced ZP1848, a glucagon-like peptide-2 agonist, into Phase I clinical trials. ZP1848, a peptide which incorporates the company’s proprietary SIP technology,
Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing, with high content phenotypic analyses in what will be a genome-scale screen using cultured
Revenues for the fourth quarter down 2% from the previous year, totaling $396.8 million. Excluding a 4% unfavorable impact from changes in foreign currency, revenues in the quarter
The Carillon system is a percutaneous treatment for functional mitral regurgitation. The CE Mark approval is an important milestone for Cardiac Dimensions, allowing the company to market the
According to the company, the new strategic business unit (SBU) is dedicated to advancing the field of interventional radiology through significant investments in the development of new medical
This is in addition to having already received the FDA’s clearance to market the company’s patented Microwave coagulation/ablation system for surgical applications. The system and single patient use
According to the company, there is a significant need for the Premier Campy test because it provides a solution to several concerns associated with culture testing, currently the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.